parlodel tablet 2.5 mg
novartis (singapore) pte ltd - bromocriptine mesylate eqv bromocriptine - tablet - 2.5 mg
parlodel bromocriptine 2.5mg (as mesilate) tablet blister pack
sandoz pty ltd - bromocriptine mesilate, quantity: 2.87 mg (equivalent: bromocriptine, qty 2.5 mg) - tablet, uncoated - excipient ingredients: maleic acid; colloidal anhydrous silica; magnesium stearate; maize starch; lactose monohydrate; disodium edetate - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con
parlodel bromocriptine 10mg (as mesilate) capsule bottle
sandoz pty ltd - bromocriptine mesilate, quantity: 11.5 mg (equivalent: bromocriptine, qty 10 mg) - capsule, hard - excipient ingredients: lactose monohydrate; gelatin; maize starch; colloidal anhydrous silica; magnesium stearate; maleic acid; titanium dioxide - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con
parlodel 2.5mg tablets
meda pharmaceuticals ltd - bromocriptine mesilate - oral tablet - 2.5mg
parlodel 5mg capsules
viatris uk healthcare ltd - bromocriptine mesilate - oral capsule - 5mg
parlodel 1mg tablets
meda pharmaceuticals ltd - bromocriptine mesilate - oral tablet - 1mg
parlodel 10mg capsules
viatris uk healthcare ltd - bromocriptine mesilate - oral capsule - 10mg
parlodel 10mg capsules
waymade healthcare plc - bromocriptine mesilate - oral capsule - 10mg
parlodel 10mg capsules
dowelhurst ltd - bromocriptine mesilate - oral capsule - 10mg
apo-bromocriptine 2,5 mg tablet
apotex sa (pty) ltd - tablet - see ingredients - each tablet contains bromocriptine mesylate equivalent to bromocriptine 2,5 mg